Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,051 - 1,100 out of 5,295

Document Document Title
WO/2001/089451A2
The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment...  
WO/2001/090081A1
This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula (I) wherein one of X, Y or Z is independently -S-,-0- CH¿2?- or $m(g)N-R?6¿, the others are -CH¿2?-; m ...  
WO/2001/087299A1
The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is admin...  
WO/2001/087834A1
A melanin-concentrating hormone antagonist which contains a compound represented by the formula or a salt thereof: (I) wherein R represents hydrogen, halogeno, or an optionally substituted cyclic group; X represents a bond or a spacer in...  
WO/2001/085696A1
The use of a compound of formula (I) in free form or in the form of a pharmaceutically acceptable salt for the preparation of a medicament for use in the treatment of rhinitis, wherein R?1¿ is phenyl that is unsubstituted or is substitu...  
WO/2001/085697A1
The present invention relates to certain substituted caporlactam carbonate and ether compounds of following formula (I): pharmaceutical compositions containing said compounds, the use of said compounds in treating tumors and to a process...  
WO/2001/085695A1
Tetrahydroisoquinoline analogs are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strengt...  
WO/2001/083444A1
The invention relates to a method for producing cyclic lactams of the formula (II), wherein n and m may each represent 0, 1, 2, 3, 4, 5, 6, 7, 8 and 9 and the sum of n + m is at least 3, preferably at least 4, R?1¿ and R?2¿ represent C...  
WO/2001/083442A1
The invention relates to a method for producing caprolactam, characterized in that a) a mixture (I) containing 6-aminocapronitrile and water in the liquid phase is converted into a mixture (II) containing caprolactam, ammonia, water, hig...  
WO/2001/083443A1
The invention relates to a method for producing caprolactam, which is characterized by a) reacting, in the presence of a catalyst, a mixture (I) that contains 6-aminocapronitrile and water in the gaseous phase to give a mixture (II) that...  
WO/2001/083441A1
The invention relates to a method for producing cyclic lactams of formula (II) by reacting a compound (I) of formula (I) with water in the presence of an organic, liquid dilution agent in the liquid phase. In formula (II), n and m respec...  
WO/2001/081349A1
A novel, optically active, quaternary ammonium salt with axial asymmetry which is useful as a phase-transfer catalyst with which a glycine derivative is stereoselectively alkylated to convert it into an optically active $g(a)-amino acid ...  
WO2001010847A3
The invention relates to novel compounds of formula (I) which bind to integrin receptors, wherein G and L have the following meaning: L is a structural element of formula IL, wherein T represents a COOH group or a radical that can be hyd...  
WO/2001/079176A1
The present invention relates to a process for the preparation of 3-[(1'-(alkoxycarbonyl)-3'-phenylpropyl)amino]-2-oxo-[1]-ben zazepine, whose derivatives are angiotensin-converting enzyme (ACE) inhibitors useful in the treatment of hype...  
WO/2001/079172A1
The invention concerns a compound of formula (I) wherein: G represents a phenyl or a heterocycle optionally substituted; G¿1? and G¿2? being N or C; T¿1? represents -CH¿2?-CH¿2?-, -CH=CH-, =CH-CH¿2?-; and T¿2? is a bond or T¿1? r...  
WO2000071518A3
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate rece...  
WO/2001/077086A1
This invention relates to novel lactams of Formula (I) having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more sp...  
WO/2001/077068A2
A process for the production of 6-aminocaproamide comprising reacting 5-cyanovaleramide with hydrogen in the presence of a metal catalyst. The 6-aminocaproamide is useful, for example, in the production of caprolactam and nylon 6.  
WO/2001/074348A2
Vasopeptidase inhibitors, especially omapatrilat, are useful in treating isolated systolic hypertension. The vasopeptidase inhibitor may be used in combination with other pharmaceutically active agents.  
WO/2001/074783A1
This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically...  
WO/2001/074784A1
This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit t...  
WO/2001/072707A2
This invention provides caspase inhibitors of formula (I): wherein Z is oxygen or sulfur; R?1¿ is hydrogen, -CHN¿2?,R, CH¿2?OR, CH¿2?SR, or -CH¿2?Y; Y is an electronegative leaving group; R?2¿ is CO¿2?H, CH¿2?CO¿2?H, or esters, ...  
WO/2001/072697A2
Process to prepare a 5-cyanovaleric acid or its ester by carbonylation of a pentenenitrile, wherein pentenenitrile is reacted with carbon monoxide and water or an alcohol in the presence of a catalyst system. The catalyst system comprise...  
WO/2001/072673A1
Anthracene derivatives of the general formula (I); and organic electroluminescent(EL) devices each having at least an organic light-emitting layer sandwiched between a pair of electrodes and containing the derivatives [wherein X and Y ar...  
WO/2001/070677A1
A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures of formula (I) (where the variables are as defined in the claims). The compounds are inhibitors of $g(g)-secretase, and hence are usef...  
WO/2001/070673A2
The present application describes novel cyclic $g(b)-amino acid derivatives of formula (I) or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O,...  
WO/2001/070232A1
The present invention provides C¿1-6?alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such...  
WO/2001/066514A1
The invention relates to a method for separating by distillation a portion or the entirety of an azeptine derivative (III), which is selected from the group consisting of aminohexylidene imine, tetrahydroazepine, hexylhexahydroazepine an...  
WO/2001/064624A1
The invention relates to a method for reducing the quantity of an unsaturated imine (III) contained in a mixture (II) containing an imine (III) and an amine (I), characterised in that the mixture (II) is treated with an oxidation agent (...  
WO/2001/056992A2
The invention relates to new processes for the preparation of the pharmaceutical oxcarbazepine as well as novel intermediates (I), (V), (VI), (VII), (IX) prepared by or used for said processes, and the preparation of said intermediates. ...  
WO/2001/055118A1
Benzene-fused heterocycle derivatives of the general formula (I); and nontoxic salts thereof (wherein each symbol is as defined in the description). The compounds of the general formula (I) exhibit inhibitory activities against cysteine ...  
WO/2001/051474A2
One aspect of the present invention relates to polypharmacophoric compounds. In certain embodiments, the polypharmacophore compounds comprise individual pharmacophore units selected from the group consisting of D-1 agonists, D-2 agonists...  
WO/2001/051479A2
The present invention provides a compound of the formula (I) and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. In said formula, X = O, (CH¿2?)¿m?, S, SO, SO¿2?, NH, NR¿8? or ...  
WO2001002358A3
The present invention relates to cyclized amide derivatives of formula (I) for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present...  
WO/2001/049665A2
The invention relates to a method for purifying lactames, especially lactames obtained by cyclization hydrolysis of an aminoalkylnitrile, and more particularly, to the purification of $g(e)-caprolactame obtained by cyclization hydrolysis...  
WO2000055137A8
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER- beta over ER- alpha . Methods are disc...  
WO/2001/046141A1
The invention relates to a method for the production of N-alkenyl amides, by reaction of the corresponding NH-amide, with acetylenes, in the liquid phase, in the presence of basic alkali metal compounds and a co-catalyst. Said co-catalys...  
WO2000077010A3
The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R<1>, R<5>, R<6a>, R<6b>, R<7>, R<8>, R<9>, X, b, k, m, and n, and the dashed l...  
WO/2001/046139A1
The invention relates to a method for producing N-alkenyl amides, by reacting the appropriate NH-amides with acetylenes in the liquid phase, in the presence of basic alkali metal compounds and a co-catalyst. According to said method, com...  
WO/2001/042208A1
Therapeutic or preventive agents for CCR5-related diseases such as AIDS, rheumatoid arthritis and nephritis, containing as the active ingredient cycloamine derivatives of general formula (I), pharmaceutically acceptable adducts of the sa...  
WO1999064041A9
Disclosed are novel multi-binding compounds (agents) which bind to NMDA receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors, thereby modulating the biological processes and/...  
WO/2001/035964A1
This invention relates to substituted 1-benzazepines and derivatives thereof useful as antibacterial agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and t...  
WO/2001/034571A1
The present invention relates $g(b)-aminoacid containing compounds of formula (I) which inhibit $g(b)-amyloid peptide release and/or its synthesis and are useful in treating Alzheimer's disease and cognition enhancement.  
WO/2001/029005A1
Compounds according to general formula (1), and pharmaceutically acceptable salts thereof, wherein V is a covalent bond or NH, X is selected from CH¿2?, O and N-alkyl, Z is either S or -CH=CH-, R?1¿ and R?2¿ are independently selected...  
WO/2001/025212A2
The invention relates to compounds of general formula (I), wherein the radicals R independently represent a hydroxy group, a hydrogen atom, a halogen atom, a pseudohalogen, a substituent, an optionally substituted alkyl radical, alkenyl ...  
WO/2001/023497A1
An organic electroluminescent element which has a high color purity, high luminescent efficiency, and long life and emits a red color; and a novel compound. The organic electroluminescent element comprises at least one pair of electrodes...  
WO/2001/023357A2
The invention comprises novel compounds of formula E-B-(Alk)¿p?-Q-(Alk)¿q?-A-G wherein G is a radical of formula (I), (II) or (III) that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated di...  
WO/2001/021305A1
The present invention relates to porous catalysts comprising layered silicate and metal oxides, and a method of preparing $g(e)-caprolactam from cyclohexanone oxime using the catalyst. This new catalyst can resolve the environmental and ...  
WO1999063936A8
Novel multi-binding compounds (agents) which bind endothelin receptors are used to treat disorders affecting the cardiovascular, renal, endocrine and nervous systems in mammals that are mediated by the endothelin receptors, such as conge...  
WO/2001/019797A2
This invention relates to novel lactams having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the pr...  

Matches 1,051 - 1,100 out of 5,295